Pegfilgrastim vs. filgrastim in reducing risk of febrile neutropenia.

被引：0
|
作者：
Lyman, GH
Bernal, M
Badamgarav, E
Pinto, L
Dubois, RW
机构：
[1] Univ Rochester, Dept Med, Rochester, NY 14627 USA
[2] Zynx Hlth Inc, Beverly Hills, CA USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4393
引用
收藏
页码：170B / 171B
页数：2
相关论文
共 50 条
  • [41] Derivation of a prognostic model for chemotherapy-induced febrile neutropenia.
    Ahn, Shin
    Lee, Yoon-Seon
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Risk factors for febrile neutropenia and the utilization of pegfilgrastim in patients receiving chemotherapy for gynecologic malignancies
    Numnum, T. M.
    Bryant, S.
    Williams, E.
    Kilgore, L.
    Straughn, J. M., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Is it appropriate to select patients for primary prophylactic use of pegfilgrastim based on the risk of febrile neutropenia?
    Narui, Kazutaka
    Ishikawa, Takashi
    Takashima, Ikumi
    Kashiwabara, Kosuke
    Uemura, Yukari
    Kikawa, Yuichiro
    Taira, Naruto
    Mukai, Hirofumi
    CANCER RESEARCH, 2024, 84 (09)
  • [44] Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia
    Aarts, Maureen J.
    Grutters, Janneke P.
    Peters, Frank P.
    Mandigers, Caroline M.
    Dercksen, M. Wouter
    Stouthard, Jacqueline M.
    Nortier, Hans J.
    van Laarhoven, Hanneke W.
    van Warmerdam, Laurence J.
    van de Wouw, Agnes J.
    Jacobs, Esther M.
    Mattijssen, Vera
    van der Rijt, Carin C.
    Smilde, Tineke J.
    van der Velden, Annette W.
    Temizkan, Mehmet
    Batman, Erdogan
    Muller, Erik W.
    van Gastel, Saskia M.
    Joore, Manuela A.
    Borm, George F.
    Tjan-Heijnen, Vivianne C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (34) : 4283 - 4289
  • [45] Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases
    Sipahi, O. R.
    Arda, B.
    Nazli-Zeka, A.
    Pullukcu, H.
    Tasbakan, M.
    Yamazhan, T.
    Ozkoren-Calik, S.
    Sipahi, H.
    Ulusoy, S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (02) : 230 - 235
  • [46] Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
    Gebremariam, Girma Tekle
    Fentie, Atalay Mulu
    Beyene, Kebede
    Sander, Beate
    Gebretekle, Gebremedhin Beedemariam
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [47] Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
    Girma Tekle Gebremariam
    Atalay Mulu Fentie
    Kebede Beyene
    Beate Sander
    Gebremedhin Beedemariam Gebretekle
    BMC Health Services Research, 22
  • [48] Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: Early hospital discharge vs. standard in-patient care
    Rapoport, BL
    Sussman, O
    Herrera, MV
    Schlaeffer, F
    Otero, JC
    Pavlovsky, S
    Iglesias, L
    Stein, G
    Charnas, R
    Heitlinger, E
    Handschin, J
    CHEMOTHERAPY, 1999, 45 (06) : 466 - 476
  • [49] COMPARATIVE EFFECT OF FILGRASTIM VS. PEGFILGRASTIM AFTER CHEMOTHERAPY ON HIGH GRADE NON HODGKIN LYMPHOMA
    Magro Mazo, E.
    Gil-Fernandez, J. J.
    Garcia Suarez, J.
    Callejas Charavia, M.
    Martin Guerrero, Y.
    Pascual Garcia, T.
    Lopez-Rubio, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 231 - 231
  • [50] A PATIENT EDUCATION APPROACH TO THE PREVENTION/EARLY DETECTION OF FEBRILE NEUTROPENIA.
    Fryar, Juanita
    Blecher, Carol
    Clyne, Timothy
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
12345